Bladder Carcinoma Clinical Trials

9 recruiting

Bladder Carcinoma Trials at a Glance

47 actively recruiting trials for bladder carcinoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in New York, Oklahoma City, and Rochester. Lead sponsors running bladder carcinoma studies include Mayo Clinic, National Cancer Institute (NCI), and City of Hope Medical Center.

Browse bladder carcinoma trials by phase

Treatments under study

About Bladder Carcinoma Clinical Trials

Looking for clinical trials for Bladder Carcinoma? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bladder Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bladder Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 47 trials

Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Advanced Bladder CarcinomaMetastatic Bladder CarcinomaStage IV Bladder Cancer AJCC v8+3 more
National Cancer Institute (NCI)60 enrolled17 locationsNCT03375307
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Phase 3

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8Recurrent Non-Muscle Invasive Bladder Carcinoma
Alliance for Clinical Trials in Oncology330 enrolled56 locationsNCT07000084
Recruiting
Phase 1Phase 2

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
Mayo Clinic40 enrolled1 locationNCT06704191
Recruiting
Phase 1

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaLocalized Muscle Invasive Bladder Urothelial Carcinoma
Shilpa Gupta, MD20 enrolled1 locationNCT05833867
Recruiting

Bladder Bank (a Prospective Banking Study)

Bladder Carcinoma
Mayo Clinic1,500 enrolled1 locationNCT06109857
Recruiting
Phase 1

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis12 enrolled1 locationNCT06173349
Recruiting
Phase 4

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Carcinoma
Ohio State University Comprehensive Cancer Center40 enrolled1 locationNCT07474519
Recruiting
Phase 1

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Intrahepatic CholangiocarcinomaGallbladder CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+5 more
City of Hope Medical Center12 enrolled1 locationNCT05285358
Recruiting

Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy

Bladder Carcinoma
Mayo Clinic1,000 enrolled1 locationNCT06891209
Recruiting
Phase 2

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Biliary Tract CancerCholangiocarcinomaGallbladder Cancer+2 more
Case Comprehensive Cancer Center27 enrolled2 locationsNCT07146646
Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Urothelial CarcinomaBladder CancerUnresectable Bladder Carcinoma+1 more
Dana-Farber Cancer Institute180 enrolled1 locationNCT06138561
Recruiting
Phase 1Phase 2

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaBladder CancerStage II Bladder Cancer AJCC v8+1 more
University of California, San Francisco47 enrolled1 locationNCT06470282
Recruiting
Not Applicable

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Urothelial CarcinomaMuscle-Invasive Bladder CarcinomaBladder Cancer+3 more
Thomas Jefferson University70 enrolled2 locationsNCT07234968
Recruiting
Phase 2

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Muscle-Invasive Bladder CarcinomaTumor
Leslie Ballas20 enrolled1 locationNCT06417190
Recruiting
Not Applicable

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Metastatic Bladder CarcinomaStage IV Bladder Cancer AJCC v8Locally Advanced Bladder Carcinoma+2 more
Roswell Park Cancer Institute160 enrolled1 locationNCT06414317
Recruiting
Phase 2

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Recurrent Bladder CarcinomaNon-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
Roswell Park Cancer Institute344 enrolled1 locationNCT06733363